These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 11560538)

  • 21. Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.
    Scholze J; Grimm E; Herrmann D; Unger T; Kintscher U
    Circulation; 2007 Apr; 115(15):1991-8. PubMed ID: 17404163
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. STORM Study Group. Sibutramine Trial of Obesity Reduction and Maintenance.
    James WP; Astrup A; Finer N; Hilsted J; Kopelman P; Rössner S; Saris WH; Van Gaal LF
    Lancet; 2000 Dec 23-30; 356(9248):2119-25. PubMed ID: 11191537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A randomized, double-blind, placebo-controlled study of sibutramine in the treatment of binge-eating disorder.
    Appolinario JC; Bacaltchuk J; Sichieri R; Claudino AM; Godoy-Matos A; Morgan C; Zanella MT; Coutinho W
    Arch Gen Psychiatry; 2003 Nov; 60(11):1109-16. PubMed ID: 14609886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A double-blind, placebo-controlled trial of sibutramine for olanzapine-associated weight gain.
    Henderson DC; Copeland PM; Daley TB; Borba CP; Cather C; Nguyen DD; Louie PM; Evins AE; Freudenreich O; Hayden D; Goff DC
    Am J Psychiatry; 2005 May; 162(5):954-62. PubMed ID: 15863798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sibutramine is effective for weight loss and diabetic control in obesity with type 2 diabetes: a randomised, double-blind, placebo-controlled study.
    Finer N; Bloom SR; Frost GS; Banks LM; Griffiths J
    Diabetes Obes Metab; 2000 Apr; 2(2):105-12. PubMed ID: 11220522
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Randomized, double-blind, placebo-controlled, multicenter study of sibutramine in obese hypertensive patients.
    Hazenberg BP
    Cardiology; 2000; 94(3):152-8. PubMed ID: 11279320
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of sibutramine-induced weight loss on cardiovascular system in obese subjects.
    de Simone G; Romano C; De Caprio C; Contaldo F; Salanitri T; di Luzio Paparatti U; Pasanisi F
    Nutr Metab Cardiovasc Dis; 2005 Feb; 15(1):24-30. PubMed ID: 15871847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced weight loss following coadministration of pramlintide with sibutramine or phentermine in a multicenter trial.
    Aronne LJ; Halseth AE; Burns CM; Miller S; Shen LZ
    Obesity (Silver Spring); 2010 Sep; 18(9):1739-46. PubMed ID: 20094043
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Weight loss and quality of life improvement in obese subjects treated with sibutramine: a double-blind randomized multicenter study.
    Di Francesco V; Sacco T; Zamboni M; Bissoli L; Zoico E; Mazzali G; Minniti A; Salanitri T; Cancelli F; Bosello O
    Ann Nutr Metab; 2007; 51(1):75-81. PubMed ID: 17356258
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation of efficacy, reliability, and tolerability of sibutramine in obese patients, with an echocardiographic study.
    Halpern A; Leite CC; Herszkowicz N; Barbato A; Costa AP
    Rev Hosp Clin Fac Med Sao Paulo; 2002; 57(3):98-102. PubMed ID: 12118266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial.
    Caterson ID; Finer N; Coutinho W; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Legler UF; Shepherd GM; Rode RA; Perdok RJ; Renz CL; James WP;
    Diabetes Obes Metab; 2012 Jun; 14(6):523-30. PubMed ID: 22192338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Randomized placebo-controlled trial of long-term treatment with sibutramine in mild to moderate obesity.
    Smith IG; Goulder MA;
    J Fam Pract; 2001 Jun; 50(6):505-12. PubMed ID: 11407998
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity.
    Gokcel A; Gumurdulu Y; Karakose H; Melek Ertorer E; Tanaci N; BascilTutuncu N; Guvener N
    Diabetes Obes Metab; 2002 Jan; 4(1):49-55. PubMed ID: 11874442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).
    Sharma AM; Caterson ID; Coutinho W; Finer N; Van Gaal L; Maggioni AP; Torp-Pedersen C; Bacher HP; Shepherd GM; James WP;
    Diabetes Obes Metab; 2009 Mar; 11(3):239-50. PubMed ID: 18671798
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [A randomized, double-blind, placebo-controlled, multicenter study on sibutramine in over-weighted and obese subjects].
    Zhao Y; Wang X; Yan Z
    Zhonghua Yu Fang Yi Xue Za Zhi; 2001 Sep; 35(5):329-32. PubMed ID: 11769634
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial.
    Tambascia MA; Geloneze B; Repetto EM; Geloneze SR; Picolo M; Magro DO
    Diabetes Obes Metab; 2003 Sep; 5(5):338-44. PubMed ID: 12940872
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 24-week, randomized, controlled trial of adjunctive sibutramine versus topiramate in the treatment of weight gain in overweight or obese patients with bipolar disorders.
    McElroy SL; Frye MA; Altshuler LL; Suppes T; Hellemann G; Black D; Mintz J; Kupka R; Nolen W; Leverich GS; Denicoff KD; Post RM; Keck PE
    Bipolar Disord; 2007 Jun; 9(4):426-34. PubMed ID: 17547588
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of sibutramine in 2225 subjects with cardiovascular risk factors: short-term, open-label, observational study.
    Gaciong Z; Placha G
    J Hum Hypertens; 2005 Sep; 19(9):737-43. PubMed ID: 15905888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long-term pharmacotherapy for obesity and overweight.
    Padwal R; Li SK; Lau DC
    Cochrane Database Syst Rev; 2003; (4):CD004094. PubMed ID: 14584004
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.